





CLL flowchart | totaaloverzicht






BEHANDEL







s concept nieuwe richtlijnen 2026






EERSTE LIJN





relaps






RELAPSED / REFRACTORY


Relapsed / refractory na eerste lijn CIT


Continue BTK remmer


Ven-R


relaps











trialleeve BTK-I

ON 165
(+ ven)

ON 180 verwacht AUMC Q3, 2026
(+ ven)

-11417-303 open in Flevo
(toclax + anti-CD20 vs. Ven-R)

-16673-302
(degrader vs. Ven-R of I-R)

(BTK degrader vs. Ven-R of I-R)

